Ipsogen, a company that markets molecular diagnostics assays for leukaemia, has launched MapQuant DxT Genomic Grade. The new assay is a molecular diagnostic test for breast tumour grade, which is an indicator of tumour proliferation, metastasis risk and response to chemotherapy.
Histological tumour grading is considered to be a decision factor in most national and international guidelines on breast cancer treatment. While it is generally recommended that high-grade breast cancer be treated with chemotherapy because it is chemosensitive, most low-grade breast tumours have a good prognosis and often do not respond to chemotherapy.
www.ipsogen.com